Danaher Co. (NYSE:DHR) Stake Lessened by Defender Capital LLC.

Defender Capital LLC. lessened its position in shares of Danaher Co. (NYSE:DHRFree Report) by 1.4% in the fourth quarter, Holdings Channel reports. The fund owned 150,885 shares of the conglomerate’s stock after selling 2,077 shares during the quarter. Danaher comprises 12.3% of Defender Capital LLC.’s investment portfolio, making the stock its 3rd biggest holding. Defender Capital LLC.’s holdings in Danaher were worth $34,906,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of DHR. Moneta Group Investment Advisors LLC lifted its position in Danaher by 96,490.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock valued at $6,180,839,000 after purchasing an additional 23,262,904 shares in the last quarter. Norges Bank bought a new position in shares of Danaher during the 4th quarter valued at approximately $2,057,164,000. Wellington Management Group LLP increased its holdings in Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after acquiring an additional 3,905,449 shares in the last quarter. Harris Associates L P bought a new stake in Danaher during the 2nd quarter worth approximately $557,074,000. Finally, Allen Investment Management LLC boosted its position in shares of Danaher by 1,440.7% in the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after purchasing an additional 1,028,976 shares during the period. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Citigroup upped their target price on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. KeyCorp lifted their price target on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. TheStreet raised shares of Danaher from a “c+” rating to a “b-” rating in a report on Friday, December 8th. Finally, Royal Bank of Canada lifted their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $266.00.

Check Out Our Latest Stock Analysis on Danaher

Insider Buying and Selling

In other news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 over the last ninety days. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of DHR stock opened at $244.26 on Thursday. The company’s 50-day simple moving average is $248.92 and its two-hundred day simple moving average is $230.38. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a market capitalization of $180.88 billion, a P/E ratio of 38.23, a P/E/G ratio of 3.74 and a beta of 0.83.

Danaher (NYSE:DHRGet Free Report) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same period in the prior year, the business earned $2.87 EPS. The business’s revenue for the quarter was down 10.2% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 16.90%.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.